On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Readies Online Sales Strategy for New InterceptCS Cold Sore Prevention Device

  • THRBF offers an IoT- and Bluetooth-enabled device for cold-sore prevention
  • Its sales strategy is part of the company’s larger focus on developing products for the dermatology market
  • THRBF’s proprietary technology is designed to prevent cold sores in the OTC sector, which is projected to record significant sales growth

Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is offering a new generation of technology in the burgeoning skin care market. The company is specifically planning to target sales growth for its high gross-margin InterceptCS* cold sore prevention device with a new website, social media campaign and online sales strategy (http://nnw.fm/f5cvQ).

THRBF’s new InterceptCS is a class II medical device that works through three 30-second treatments and offers multi-use activators. Therma Bright’s strategy is to market the product online through distributors and a new social media campaign, as well as on its new website at www.ColdSores.com.

Toronto-based THRBF offers first-rate medical devices for dermatological needs. The company focuses on proprietary technology in the OTC pain-free and noninvasive sectors, and it has received class II medical device status from the U.S. Food and Drug Administration (FDA). Therma Bright also markets TherOZap, an insect-bite treatment device.

The dermatology market is estimated to reach $22.6 billion in the United States by 2028, according to GMR Data (http://nnw.fm/E5lYd).

* Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome,” by Health Canada. InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficac, and/or cure or prevention of disease.

For more information, visit the company’s website at www.ThermaBright.com

NOTE TO INVESTORS: The latest news and updates relating to THRBF are available in the company’s newsroom at http://nnw.fm/THRBF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217